<DOC>
	<DOCNO>NCT00292929</DOCNO>
	<brief_summary>The purpose study establish safety , tolerability pharmacokinetics single dose antimalarial drug artesunate .</brief_summary>
	<brief_title>Study Safety Intravenous Artesunate</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Cerebral</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Healthy adult male nonpregnant , nonlactating female Have normal ECG may include benign PAC 's PVC 's , 1st degree AV block , 2nd degree AV block , Wenckebach Have normal blood pressure ( BP ) heart rate ( HR ) . These measure rest supine 3 minute . Normal BP define less 140 mm Hg systolic le 90 mm Hg diastolic . Normal baseline HR 50 90 bpm without symptom . Body mass index 18 29 kg/m**2 , range , clinically significant ( within 15 % ideal body weight ) . Be able verbalize understanding consent form , provide write informed consent verbalize willingness complete study procedure Have brief physical examination demonstrate clinically significant contraindication participate study . If female , negative serum pregnancy test screen urine pregnancy admission postmenopausal , hysterectomy , sterilize , agree practice effective contraception duration fo study period 12 week stop study drug . Have receive investigational drug vaccine period 0 16 week entry study . Have liquid protein diet last year Have clinically significant abnormal physical finding screen examination Have clinically significant abnormality result laboratory screen evaluation Have use prescription drug within 14 day prior admission nonprescription drug ( include herbal dietary supplement ) within 7 day prior admission Existence surgical medical condition , judgement clinical investigator , might interfere distribution , metabolism excretion drug Presence history drug allergy require treatment . Hay fever allow unless active require treatment within previous 2 month Donation loss great 400 ml blood period 0 12 week entry study . Serious adverse reaction hypersensitivity drug , particularly artemisinins CAGE ( screen test alcoholism ) positive ( 2 4 criterion ) history recent alcohol abuse Use illicit drug Family history sudden cardiac death prolong QT syndrome ( defined 500 msec note repeat tracing ) History seizure , syncope , trouble hear balance neurological disorder History severe psychiatric disorder hospitalization severe psychiatric disorder Current job personal habit reverse sleepwake cycle History cardiac disease include cardiomyopathy , valvular disease , arrhythmia , ischemia , enlarge heart Presence hepatitis B surface antigen ( HbsAg ) , hepatitis C antibody ( antiHCV ) HIV type 1 screening Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>artesunate</keyword>
	<keyword>artemisinin</keyword>
	<keyword>falciparum</keyword>
</DOC>